Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages 1031-1037

  Kastritis, Efstathios ^a   Wechalekar, Ashutosh D ^a   Dimopoulos, Meletios A ^a   Merlini, Giampaolo ^a   Hawkins, Philip N ^a   Perfetti, Vittorio ^a   Gillmore, Julian D ^a   Palladini, Giovanni ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHIC PAIN; NEUROPATHY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIMARY SYSTEMIC AMYLOID LIGHT CHAIN AMYLOIDOSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77949897868     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8220     Document Type: Article

References (42)

1. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596, 2003 (Pubitemid 36951371)
2. Dispenzieri A, Lacy MQ, Rajkumar SV, et al: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10:257-261, 2003 (Pubitemid 38117510)
3. Palladini G, Perfetti V, Perlini S, et al: The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949-2951, 2005 (Pubitemid 40446290)
4. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470, 2007 (Pubitemid 46105939)
5. Sanchorawala V, Wright DG, Rosenzweig M, et al: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 109:492-496, 2007 (Pubitemid 46105943)
6. Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276-4282, 2002 (Pubitemid 34627192)
7. Kyle RA, Gertz MA, Greipp PR, et al: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207, 1997 (Pubitemid 27183649)
8. Palladini G, Perfetti V, Obici L, et al: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936-2938, 2004 (Pubitemid 38451663)
9. Palladini G, Russo P, Nuvolone M, et al: Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110:787-788, 2007 (Pubitemid 47105419)
10. Jaccard A, Moreau P, Leblond V, et al: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-1093, 2007 (Pubitemid 47443213)
11. Sanchorawala V, Skinner M, Quillen K, et al: Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 110:3561-3563, 2007 (Pubitemid 350159622)
12. Wechalekar AD, Goodman HJ, Lachmann HJ, et al: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457-464, 2007 (Pubitemid 46105938)
13. Lebovic D, Hoffman J, Levine BM, et al: Predictors of survival in patients with systemic lightchain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143:369-373, 2008
14. Palladini G, Russo P, Lavatelli F, et al: Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 88:347-350, 2009
15. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003 (Pubitemid 36741588)
16. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005 (Pubitemid 41007864)
17. Harousseau JL, Attal M, Leleu X, et al: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91:1498-1505, 2006 (Pubitemid 44736116)
18. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
19. Kastritis E, Anagnostopoulos A, Roussou M, et al: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92:1351-1358, 2007 (Pubitemid 350144152)
20. Wechalekar AD, Lachmann HJ, Offer M, et al: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 93:295-298, 2008 (Pubitemid 351397721)
21. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328, 2005
22. Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program 257-282, 2004
23. Dispenzieri A, Gertz MA, Kyle RA, et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757, 2004 (Pubitemid 41095215)
24. Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003 (Pubitemid 36605226)
25. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 26:3913-3915, 2008
26. Palladini G, Lavatelli F, Russo P, et al: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858, 2006 (Pubitemid 43726787)
27. Sitia R, Braakman I: Quality control in the endoplasmic reticulum protein factory. Nature 426: 891-894, 2003 (Pubitemid 38056881)
28. Breckenridge DG, Germain M, Mathai JP, et al: Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22:8608-8618, 2003 (Pubitemid 38019196)
29. Teixeira PF, Cerca F, Santos SD, et al: Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 281:21998-22003, 2006 (Pubitemid 44181903)
30. Huang CJ, Haataja L, Gurlo T, et al: Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 293:E1656-E1662, 2007 (Pubitemid 350255116)
31. Keller JN, Hanni KB, Markesbery WR: Impaired proteasome function in Alzheimer's disease. J Neurochem 75:436-439, 2000 (Pubitemid 30418211)
32. Casas S, Gomis R, Gribble FM, et al: Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis. Diabetes 56:2284-2294, 2007 (Pubitemid 47358235)
33. Bianchi G, Oliva L, Cascio P, et al: The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113:3040-3049, 2009
34. Sitia R, Palladini G, Merlini G: Bortezomib in the treatment of AL amyloidosis: Targeted therapy? Haematologica 92:1302-1307, 2007
35. Palladini G, Anesi E, Perfetti V, et al: A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113:1044-1046, 2001 (Pubitemid 32634774)
36. Gertz MA, Lacy MQ, Dispenzieri A: Therapy for immunoglobulin light chain amyloidosis: The new and the old. Blood Rev 18:17-37, 2004 (Pubitemid 38200499)
37. Lachmann HJ, Gallimore R, Gillmore JD, et al: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78-84, 2003 (Pubitemid 36819341)
38. Dispenzieri A, Kyle RA, Gertz MA, et al: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361: 1787-1789, 2003 (Pubitemid 36638428)
39. Brenner DA, Jain M, Pimentel DR, et al: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94:1008-1010, 2004 (Pubitemid 38579694)
40. Dember LM, Sanchorawala V, Seldin DC, et al: Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 134:746-753, 2001 (Pubitemid 32402067)
41. Chanan-Khan AA, Kaufman JL, Mehta J, et al: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 109:2604-2606, 2007 (Pubitemid 46425908)
42. Roussou M, Kastritis E, Migkou M, et al: Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49:890-895, 2008 (Pubitemid 351942741)